Geert Berx

Dr. Geert Berx


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2013 in Nature Reviews Cancer
Verified
Journal Article
Closed access
BCBram De Craene
Bram De Craene
GBGeert Berx
Geert Berx

28 February 2017 in Nature Methods
Verified
Journal Article
Closed access
ECEV-TRACK Consortium
EV-TRACK Consortium
JDJan Van Deun
Jan Van Deun
PMPieter Mestdagh
Pieter Mestdagh
PAPatrizia Agostinis
Patrizia Agostinis
ÖAÖzden Akay
Özden Akay
AHAn Hendrix
An Hendrix

1 June 2001 in Molecular Cell
Verified
Journal Article
Closed access
JCJoke Comijn
Joke Comijn
GBGeert Berx
Geert Berx
PVPetra Vermassen
Petra Vermassen
KVKristin Verschueren
Kristin Verschueren
Leo van GrunsvenLeo van Grunsven
Leo van Grunsven
FRFrans van Roy
Frans van Roy

6 May 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
HHHannah Van Hove
Hannah Van Hove
LMLiesbet Martens
Liesbet Martens
ISIsabelle Scheyltjens
Isabelle Scheyltjens
KVKaren De Vlaminck
Karen De Vlaminck
AAAna Rita Pombo Antunes
Ana Rita Pombo Antunes
KMKiavash Movahedi
Kiavash Movahedi

17 January 2005 in Oncogene
Verified
Journal Article
Closed access
PDF file
AEAndreas Eger
Andreas Eger
KAKirsten Aigner
Kirsten Aigner
SSStefan Sonderegger
Stefan Sonderegger
BDBrigitta Dampier
Brigitta Dampier
SOSusanne Oehler
Susanne Oehler
RFRoland Foisner
Roland Foisner

23 September 2009 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Closed access
PDF file
GBGeert Berx
Geert Berx
FRFrans van Roy
Frans van Roy
We review the role of cadherins and cadherin-related proteins in human cancer. Cellular and animal models for human cancer are also dealt with whenever appropriate. E-cadherin is the prototype of the large cadherin superfamily and is renowned for its potent malignancy suppressing activity. Different mechanisms for inactivating E-cadherin/CDH1 have been identified in human cancers: inherited and somatic mutations, aberrant protein processing, increased promoter methylation, and induction of transcriptional repressors such as Snail and ZEB family members. The latter induce epithelial mesenchymal transition, which is also associated with induction of “mesenchymal” cadherins, a hallmark of tumor progression. VE-cadherin/CDH5 plays a role in tumor-associated angiogenesis. The atypical T-cadherin/CDH13 is often silenced in cancer cells but up-regulated in tumor vasculature. The review also covers the status of protocadherins and several other cadherin-related molecules in human cancer. Perspectives for emerging cadherin-related anticancer therapies are given.